Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Xvivo, Audiocast, Q1'25

By Inderes4/24/2025, 12:00 PM
Xvivo Perfusion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christoffer Rosenblad
00:00 - 19:30

Good morning and good afternoon. And welcome to XVIVO. XVIVO's earnings call for the first quarter of 2025. Um, as stated earlier, the presenters today are me, Christoffer Rosenblad, CEO for XVIVO, and Kristoffer Nordström, CFO. And with that, we can go over to the second slide. Q1 financials at a glance. And I'm proud and happy to report that Q1 shows improvement in the top line as well as EBITDA compared to the same quarter last year. Q1 once again demonstrates that XVIVO has a scalable business model with improving margins as it continues to expand. Even though we have continued to invest heavily into the organization for future growth. The quarter was very strong from a North American regulatory perspective, with many milestones passed. For example, the Liver ID was approved, and we can now start our trial in the United States. The Heart CAP was approved, and the HART trial directors now have access to the Lifesaving Heart technology in the US for a limited number of patients. And lastly, Health Canada approved our liver and kidney technology, which opened up that market for our Abdominal portfolio. If you look at the slide, sales came in at SEK 219 million. The gross margins continue to show strength, and we have a scalable production setup. We plan to improve the Abdominal gross margin to 70% at the latest in 2027 or earlier, when we reach economies of scale in production. The EBITDA shows an improvement to 21%, and Kristoffer Nordström, our CFO, will later get into the details on sales, gross margin, and EBITDA. Uh, the gross showed a mixed picture during the quarter. In thorax, we see the highest ever interest to start an EVLP program, but sales growth came in lower than we expected. Uh, of course, the lack of heart transplant sales both in the US trial and from Europe hampers the growth. The good news is that, besides, the cap is now approved in the US. We also see that the heart sector in Australia is growing very fast with an Australian growth rate of 60%. Q1, the penetration last year was approximately 30% for Australia heart. And we saw a slight increase during Q1. The high interest and the Australian experience once again showed that the heart technology has the potential to change the paradigm of heart transplantation, and we get more and more customer testimonials that this is the case. And the Abdominal sales showed strength during the quarter. In the US, cath disposables grew 100%, albeit from low levels, and in Europe, both liver and kidney showed strong growth based on excellent clinical and hospital economic data. Um, we are not pleased with the progress in our US service business. At first glance, the Italian model with the Perfusionist works very well, and we will spearhead a Perfusionist model initiative in the US already in Q2 this year. We acknowledge that the service business is crucial for the heart launch, and when the strategic review is finished, we will come back with a plan forward for the US services business. Lastly, and most importantly, it is worth mentioning that the projects are progressing according to plan. The Heart project is still on time and budget, albeit we didn't expect a long review from the EMA and the Swedish Medical Agency due to the high workload at these two European agencies. The Production Capacity project is where we invest to scale up volumes tenfold. Up-to-date volumes for disposables are running in line with the communicated timelines. The full-scale production of disposables for heart, liver, and kidney will be extremely important to capture the future growth potential for all three product groups. And with that, we can go to slide three, which is the highlights of Q1. Uh, the picture in front of us reminds us all why we're here. And that is to ensure that no one dies waiting for an organ. Uh, Alex in this picture is one of the 400 patients who got the opportunity for a heart transplant. Thanks to our innovative heart technology. We start with regulatory highlights. Uh, so we can quickly go to slide five. And, um, the progress on the US heart PRESERVE Heart Trial is noteworthy. Uh, we are pleased that the Continuous Access Protocol is now approved and that we can give access to the heart technology to a limited number of patients in the trial sites. Besides that, the Continuous Access Protocol will strengthen the clinical file with more patient data in the US. The heart technology so far has surprised us positively every time it has been used, and more data will be key to building a solid clinical file. And again, I want to remind us all that the 13-month enrollment was a record time for the clinical trial, five months ahead of schedule. It has also been seen in the United States. With that, we can go over to slide six and our liver trial. The DeLIVER Trial, um, the IDE or investigational device exemption, was approved during the quarter for the liver. Key takeaways are that, one, the liver technology is market-leading in Europe, and more than 20 clinical papers from the last 12 months show superiority in graft survival for both short- and long-term hospital economics, where the liver saves more than €25,000 per transplant due to lower aftercare costs. And lastly, by using the Liver Assist, surgical teams can not only see better patient survival and hospital economics but also improved work-life balance with morning surgeries. The liver growth in Europe is partly driven by the 2024 Cochrane Review and the 1,200 patient real-world data. The Cochrane Review supports the implementation of Hypothermic Oxygenated Perfusion (HOPE) with Liver Assist as a routine practice for liver transplantation. With the ID approved, we can now start the clinical trial in the US that will form the basis for our PMA application with the FDA. The trial will enroll 215 patients at a maximum of 20 clinics. The inclusion criteria for the trial are extended criteria livers, i.e. Very similar to the heart trial we just concluded in terms of patient inclusion. The work with CMS for site reimbursement and the hospital for both ethical approval and site contract is underway. We know from experience that this work takes some time, and the plan for the first patient is during Q3 this year. In conclusion, we are very excited that the technology has evolved. The lives of many patients in Europe can now be improved as American transplant clinics have access under the trial. And with that, we can go over to the last, uh, regulatory highlight. And it's on slide seven, which is the regulatory highlight from Canada. During the quarter, we received MDSAP approval and subsequently Health Canada approval for our liver and kidney products, and we have hired our first employee to facilitate our launch there in Canada. We have a full Abdominal team in the US that will support the launch of Kidney Assist Transport and Liver Assist. Canada is also interesting from a US perspective where surgeons are very cooperative and often collaborate across the Canadian border, which will be helpful also for the later US launch. So we know that learnings in Canada can be deployed on a surgeon-to-surgeon basis into the US as well. Um, lastly, the heart launch in Canada will depend on obtaining a CE mark. We first get a CE mark, and based on the CE mark, Health Canada will make its own judgment based on the file and the CE mark. So we have to wait for the heart in Canada. But we are very pleased that we can now start working with the abdominal products in Canada, where we know there has been a demand for getting our products approved. And with that, we go to slide eight, which is the overview of where we have regulatory status. This data shows that we are still working on approvals for heart in all core markets and liver in the US. With the recent good news in Canada, it will be considered a core market as of now. But this slide hasn't yet been updated to reflect that. And with that, we can go to slide nine, which covers the timeline and the progress of regulatory processes. We see constant progress, and I believe Q1 is a testament to that. There is progress in each process, but the key message is the same as last time we met. So I would partly repeat what I said in January 2025. The trial is, as you know, fully enrolled in record time. Next milestone is the 12-month patient follow-up. In parallel, we will prepare the clinical and preclinical file for submission, as well as expand the clinical file with the help of CAP data, or continuous access protocol data. After the 12-month follow-up time and some time for database lock, we can start preparing the clinical file for submission as well. As mentioned before, in Europe, we have submitted our technical documentation for review according to our timeline. In dialogue with our notified body, we understood that the heart box is already approved. This enables us to talk to clinics about the heart box. The insecurity we still face is how fast the EMA, which is the European Medicines Agency, and the Swedish MPA can handle their review time. They are under a lot of stress due to MDR, so we do not yet have full insight into their timelines today. However, we are ready to launch when the product is approved. So the launch plan is ready. Staff is recruited, and the interest from clinics in Europe is very, very high for the product. As I stated earlier on this call, in Australia and New Zealand, we have seen high usage of the product. The regulatory approval will be pending the CE mark in Europe and the same will apply for Canada. We have initiated DCD data collection in the United States as part of the trial in Europe as part of a 40-patient trial, and we will initiate the same type of data collection. Uh. Uh, and data application and trial in Australia as well to get DCD data in Australia to have full usage of the hot box once approved. And lastly, the liver. We have gone over that one, but we have been granted breakthrough device designation by the FDA and we didn't get the approved IDE. We are working hard to get the trial started in Q3 this year. So with that, we can go to the next slide, which is the ISHLT 2025 and the expected highlights, which the ISHLT will be next week in Boston. It's a key event for lung and heart transplant surgeons during the year. Uh, we will have five days of meetings and, uh, excellent presentations of new data. The most important speech during the conference, we believe, will be the one-year follow-up of the trial data. Last year, Prof. Rega presented a 76% risk reduction in severe PGD, which is the leading cause of early and late mortality after a heart transplant. This year, he will present how well the patients are doing after one year. We are all eagerly looking forward to that presentation. We are also looking forward to the novel trial presentation by Dr. Sanchez and to our two industry symposia. Last year, they were packed to the brink of the room, and people had to stand up lining the walls. The general view was also that the symposia we led had a higher scientific level than most of the ordinary programme, which is a great testament to our marketing team and clinical team who prepared those two symposia. We aim to repeat that 2024 success also in 2025, in Boston. So you will hear more of this when we meet next time in July. And with that, we can go over to their business operations on slide 11, and we can go straight into slide 12, where we start with the surrounding world. And the key message is that we will continue to invest to make sure that no one dies waiting for an organ. If we start with trade policies, we see a constantly changing environment and we have plans for each scenario. Currently, we have production in the United States for the Lung XPS and part of the lung kit, while we produce heart, liver, and kidney products as well as disposable and sterile products in Europe. We know, for example, that PERFADEX accounts for somewhere between 0.2% and 0.3% of the total cost for a lung transplant in the US, and that a price increase will not affect the number of heart transplants in the US. Um. It is important to always prioritize patient safety. It's better for the patient if we maintain a stable production of sterile products with high-quality goods to ensure they will survive a lung transplant rather than if the price is 10% higher than it is today. For machines that are not sterile, we aim to set up dual production. In other words, we will in the future have one production site in the United States and one in Europe. Uh, in terms of investment into the organization, we will continue to invest heavily in the US organization. And we will soon open a new R&D and academy in Denver, Colorado. In parallel, we continue to invest in commercial R&D and regulatory capabilities in the United States. If we turn to the next slide. We will provide more detailed segment updates as we delve deeper. And I will give a more detailed overview of where we are and what actions we will take. As stated earlier, the heart is performing very well in regions where we are permitted to sell the product, which currently includes Australia. Uh, we are preparing for the EU launch, uh, for lungs. Uh, we have seen a very good last year, uh, a softer Q1 with an extremely high interest to start an EVLP program. The new commercial force we put in place in Q4 2023 has now been up and running for approximately a year. And the key learnings are that, one, we will invest in more clinical representatives closer to customers. Too many customers need on-site support with Perfusionists, and hence we will try the Italian model, which has been working very well in Italy with on-site perfusion and three. We know that hub models work. We need to encourage more clinics in the US to adopt the model used in Paris, where one clinic or one OPO evaluates lungs for multiple clinics. The good example we see is that we see a lot higher usage of lungs around the two lung bioengineering hubs in the United States, which is a testament that hub models work. I also want to highlight that during the quarter, two great publications were released around LP and lungs, one showing that lungs on LP showed good patient survival for high-risk patients, and high-risk recipients also came out significantly better than competing products during that trial. The second publication is very encouraging, showing that an EVLP program is economically beneficial for clinics if they perform more than three EVLP lung transplants per year. If we go into the Abdominal business, it's showing good progress in Europe. Liver is the growth driver, but interest in kidneys is picking up. So now we are hitting clinical doors in, or hospital doors in the US, while the majority of kidney perfusions are done in the OPOs. But that will take another couple of 4 to 6 quarters before we have the right product and the right clinical data to really see good performance on Cat in the U.S. And we can go to slide 14, which is the last before our CFO takes over and we look at the US organ recovery service. In short, it can be said there is a large need for organ recovery services in the United States, especially if they're paired with perfusionist services. So the combined service of an organ recovery service and perfusion is also strategically important for the heart. Laws in the United States. The other thing that we can conclude is that we are not pleased with the current performance, and are currently conducting a full strategic review of our US services business. We will come back when that one is finished in June. Um, we are continuing to invest in FlowHawk, so they are in a few clinics in the US, but where the FlowHawk software is, it's very well appreciated and adds value to the clinics. So we will continue to invest in that integration. And with that, I say thank you for this part of the presentation. And we can turn over to slide 15. And actually, Kristoffer, you will take over from here.

Kristoffer Nordström
19:32 - 30:29

I will. Kristoffer. So we will continue to invest in that integration. So we will continue to invest in that integration. So let's move on to the financial section here. And starting with the net sales and key ratios for the quarter. This was a quarter where sales performance varied slightly among our three business areas. And I will shed some light on each area later on. Overall, the underlying trends for our current businesses are positive for both Thoracic and Abdominal. As we increase our customer base, we continue to see a growing demand for technologies on the services side. As Kristoffer mentioned, we have work to do in order to accelerate these businesses. Worth highlighting is that this was a quarter where we lacked some revenue that we had last year. So, for example, revenue from trials in the US, and as a comparison, last year we had 7 million SEK in revenue from our heart trial. But let's move on to the numbers. Net sales were 219 million SEK and organic growth was 14%. If we look at the rolling 12 months as we prefer to do, the organic growth was 33%. Overall, the gross margin was in line with last year at 73%. Adjusted EBIT increased by 50%. That's a lot in SEK and reached a margin of 14%, strengthened from 11% last year. And finally, EBITDA was 21%, an improvement over the 20% of last year. Um, we did not see any major effects on our P&L from the weakened US dollar in Q1. As you know, we have a high portion of our business in the US. Um, and I will provide some comments on this topic in a few slides when we dig down a little bit on the EBITDA. But moving over to the Thoracic business area, total sales in Q1 amounted to 142 million SEK, which is an organic growth of 16%. The rolling 12 months organic growth is 39% after a strong sales quarter in Q4. From a pure sales number perspective, this quarter was weaker. But EVLP is not always a quarterly stable business. Uh, we need to live with that. Um, as we grow bigger, longer trends provide a better understanding of the trajectory we're on. And B, I will provide some useful insights by digging into some details here. So, um, for lungs, sales grew by 18% in local currencies. Uh, that's softer growth than the previous quarters. Um, however, uh, we truly want to emphasize that the underlying health of our business is stronger than this number suggests. Last year's comparative numbers were to some extent inflated by research sales, and this Q1, we could not onboard our new XPS customers until the very last weeks of the quarter, which led to some reduced growth compared to our own forecasts. However, the quarter finished strongly and four XPS devices were sold in the last weeks. So, two in the US and two in Europe, to France and the UK, by the way, and the XPS interest remains very high. And we truly believe that 2025 can really be a record year for us in terms of XPS programs started. Um, as we mentioned in the report, we will still face some limitations on the XPS production capacity in the next two quarters, and we forecast that we will be able to produce around three XPS machines per quarter for the year. Um, gross margin. I mean, stable, 82%, one percentage unit better than last year. So, sales were SEK 8 million this quarter versus SEK 12 million last year. However, we had around 7 million SEK worth from the US heart trial last year. This means that, even when excluding the US heart trial results. We grow quite nicely here. Um, what stands out and what we're extremely proud of is the development we see in Australia. So this quarter, they brought in 6 million SEK of revenue, with a growth of 61%, as Kristoffer mentioned. And it really demonstrates the huge enthusiasm they have for our technology in that region. So to conclude, Thoracic, I mean, heart shows improved momentum in Australia and also Europe, with some compassionate use cases there as well. Uh, and we're waiting to see market developments. You know, the Lung segment had a little bit of a softer quarter, but the underlying health is good. And we will remain the partner of choice. Uh, based on the order books that we see for the XPS devices globally, for all the customers who want to set up an EVLP program in 2025? Abdominal net sales in Q1 came in at 57 million, and the organic growth was 28%, very much in line with the rolling 12-month growth that we see at 31%. So I would say it's a business-as-usual quarter, but in a positive way, because we continue to grow in Europe. On our main market, livers accounted for 75% of Abdominal sales and kidneys for 25%. So here we start to see now some growth in both the US and Europe for the kidneys. Transport, although still from small numbers. We know that, but we're getting there. Um, as an example, in the US, the disposable sales for transport grew by 108%, so we doubled the sales there. The gross margin for disposables decreased from 68% last year to 63%. Uh, I think we need to live with some fluctuations here in Abdominal in the next, you know, 1 or 2 years until we achieve some economies of scale. Um, but the primary reason this year was a higher proportion of distribution sales, and some higher research sales from last year with higher margins. But a solid quarter for Abdominal, in my opinion. Last business area. Moving over to services. Sales amounted to SEK 20 million organically. Sales from organ recovery decreased by 19% due to a lower activity volume, while the acquisition of FlowHawk contributed positively with an acquired growth of 13%. So all in all, there was a -6% decrease compared to last year. On a positive note, we signed new recovery service agreements with three clinics in Q1, and we look forward to starting to serve these clinics in Q2. Um, this margin is expected to strengthen gradually as the recovery volumes increase. But most notably, when sales of FlowHawk increase, which is a SaaS product with margins similar to a lung portfolio, if not even better, in Q1, we had integration costs here. We continue to build and integrate this offering. So we had integration costs of 3 million SEK. As we continue to further build and integrate FlowHawk into the service offering, we aim to further develop and define our service offerings. A strategic review, as Kristoffer mentioned, will take place here in the next few months. Um, a project we have also started to work on is to look at how FlowHawk could be connected also with our various perfusion devices over time here in the future. Two more slides before I'll hand over to Kristoffer again. Uh, EBITDA profitability came in at 21% in Q1, uh, 1% better than last year. And at rolling 12 months, we're at 22%. Um, yeah, sounding like a broken record, but we've stated it before. Our ambition is to continue to improve EBITDA year on year, but we want to do that in a controlled way so we maintain a healthy relationship between sales growth and sustainable profitability development. Um, as I stated in my introduction, Q1 was not negatively impacted by the weakening of the US dollar against SEK in the PNL. Uh, most likely we will see, um, a fairly large impact in our numbers during the rest of the year though, uh, and to provide some guidance, uh, we could look into the past. Right. So, uh, if we look at last year's numbers in terms of sales, approximately 60% of our sales were in US dollars, and we have most of our COGS in euros and SEK. And if the USD against the SEK in 2024 was 10.5, roughly a decrease to 9.5 as we see now in 2024 would have led to a decrease in net sales last year of 45 million SEK, and that, in turn, would result in a decrease of EBITDA of approximately 20 million, or 1% unit on the EBITDA margin last year. So I hope that provides some guidance here on what we can expect for the future. Final slide. Cash flow and financial position. Q1 operating cash flow was -15 million SEK. No concerns there. Primarily due to a payment of our annual employee bonuses for 2020. If we had that, it would have positively impacted the operating cash flow. Um, we continue to invest. Investments amounted to 59 million SEK. Um, as always, that's primarily spent on the US clinical trials but also on the production project. Billy. Um, we ended the year with a solid cash position of 316 million SEK, uh, after exchange rate effects on cash of 22 million SEK. And finally, as we announced in the last call, we have entered into a revolving credit facility of €20 million here in January, which currently remains unutilized. And with that, I will give the word over to you again, Kristoffer, for the outlook. Final slide.

Christoffer Rosenblad
30:29 - 34:00

Thank you so much. Yes, we will look into, as usual, first what to expect during the year. Um, and I think the first thing is that we see a very high interest in starting an EVLP program, and we will invest to capture that interest, both in terms of headcount and possible perfusionist services. Uh, we have stated that we have a scarcity of XPS machines right now, and we do see that we will have more XPS machines in the second half of the year than in the first. So we will come back. When we see that production picking up for heart, we will continue to prepare for the launch in Europe and Australia. We will continue to prepare for the launch in Europe and Australia. We will continue to build the US regulatory and clinical file for heart and liver. The excellent clinical data was published. We will invest in commercial capabilities in Europe to capture the growth opportunity we see here, and we aim to start our clinical PMA trial during Q3 this year. So those are the milestones from a regulatory viewpoint. Lastly, I also want to stress that we see great investment potential during 2025 with a return on investment of approximately one year, and we will invest in those opportunities. Key commercial investments include the EU heart launch. Strengthening the kidney US launch. Strengthening the US lung business as well as the Abdominal launch in Canada. We will continue to invest in the supply chain and quality department, and the regulatory department to capture the increasing customer demand for our products. Uh, and I also want to stress that we are building up our inventory levels. Uh, we have taken out a revolving credit facility to do that. So we will see increasing inventory levels during this year. That is a planned action we undertake to ensure that we can always deliver products to our customers. And if we look into a longer-term outlook, which is the important one and the reason why we are here, we see that the demand for transplants is still ten times higher than the supply, according to W.H.O. . The sales value of machine perfusion is approximately ten times that of static perfusion, which is typically a beer cooler type of box with ice and solution. The main growth drivers are superior clinical results from machine perfusion, and the fact that service models reduce complexity and time for the transplant clinic. Hence, machine perfusion and the service model are crucial, and DCD grafts will continue to drive growth in the near future and the long-term future. Xvivo has a unique and proven product platform to one day accomplish that. No one will die waiting for an organ. And with that, I turn to the next page 24. Thank you for listening today. And with that, we open up the lines for questions.

Operator
34:03 - 34:22

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Ulrich Trattner from Carnegie. Please go ahead.

Ulrich Trattner
34:25 - 35:35

Thank you very much. And hi, Christopher and Christopher, I have a few questions on my end. Um, starting off with this Canada opportunity that has emerged, and as you've already stated, we have long been on the market in Canada, but now are expanding that into the catheter products as well as the DeLIVER product. And just if you can give us kind of a scope of how many sort of addressable organs there are and how the dynamic looks like, and are you facing the same type of competition in Canada as they do in the US, i.e. that Transmedics is considered the leading product provider for organ perfusion technologies. For liver and other legacy products for kidney, as well as the follow-up question to that, do they experience the same type of limitation on the cath product in Canada in terms of the dual oxygenation ducts to the arteries, as well as being larger kidneys? Um, that needs to be adjusted in terms of the consumable; that would be my first question.

Christoffer Rosenblad
35:36 - 37:18

Uh, and I also want to stress that we are building up our inventory levels. Thank you. Rick. Um, to start off with your first part of the question, Canada is similar in size in terms of market opportunity when compared to a big European market like France, etc. Uh, and I also want to stress that we are building up our inventory levels. So it's definitely a core market for us. Canada could also act as a bridge into the United States due to a close relationship between surgeons in Canada and the US across the border. So that's why it's important. And the market dynamics are more similar to Europe than the United States in terms of competition. Uh, and in terms of the kidney product, we have to see how some of the needs are similar, like the dual or triple shoulder, which will be the same in the US and Canada. Um, but the system with a clinician going out to recover organs is more similar to Europe than the United States, where the majority of the work is done in OPUS facilities. So it will be a mix of us and Canada, and we hope we can learn a lot from Canada, both in terms of meeting key opinion leaders, learning from them, acquiring more clinical data that will not be totally applicable to the US, but still reasonably applicable. What was the second part of your question? I forgot that I asked the first part.

Ulrich Trattner
37:18 - 37:51

Um, I think you answered most of it. It was just more on how big the market is as well. Yeah. In similarities to that of the US, I think you answered all of it, but a full question on that would be what is the planned ramp-up here? I did note that you mentioned that you have hired your first representative in that market, but how should we view this sort of step-up here throughout 2025?

Christoffer Rosenblad
37:53 - 37:56

Sorry, your line is a bit broken. Can you try to repeat?

Kristoffer Nordström
37:57 - 37:58

We have hired our first.

Ulrich Trattner
37:59 - 37:59

Yeah.

Kristoffer Nordström
38:00 - 38:06

Yeah. First employee. Christoffer Rosenblad. So how do you plan to expand the organization timeline for that in Canada?

Christoffer Rosenblad
38:07 - 38:45

Okay, great. Yeah, we have hired our first employee, and initially, we will support from the US Abdominal team. Uh, and we will come back somewhere during Q4 with a ramp-up plan, depending on how it's going. Um, but geographically, it's a big market. Absolutely. But in terms of the number of clinics, it's smaller, so to say. So, uh, we don't foresee having a huge sales force in Canada if that answers the question.

Ulrich Trattner
38:47 - 39:15

So it's definitely a core market for us. Yeah, sure. And if we were to stick to the current product and focus on tweaking and updating the product, as well as acquiring clinical data. It sounds like from your statement that we should expect that to be resolved closer to 2026 rather than the end of this year, which sounds like a bit of a delay from the previous statement. Is that a fair assumption?

Christoffer Rosenblad
39:16 - 39:51

Yeah, that is a fair assumption. Part of it will be solved during the year concerning patch holders. Uh, insights suggest the larger reservoir will probably be implemented in 2026. Uh, clinical data will be acquired, uh, gradually through this year and next year. But as we know, it takes time to gather clinical data and also publish it, so we probably have to think more in terms of 4 to 6 quarters than anything else before we can go full, full. Head into the approvals.

Ulrich Trattner
39:53 - 40:14

Yeah, right. Um, as well, as you mentioned, I'm not sure if I got this right, that you're expanding your service offering similar to that of Italy from Q2. If you could just remind me what you said and potentially clarify on how that is planned to be expanded throughout 2025.

Christoffer Rosenblad
40:15 - 41:00

Yeah, we will try it during Q2. Um, we have always believed in the Italian model but have not been very successful with it in the US. So we will now spearhead a project in 1 to 3 locations, depending on how long it takes to get through the hospital administration, where we pair an EVLP service with the Perfusionist. Uh, we know that the need, I would say, is that probably the biggest hurdle for EVLP growth now is resources. That's my judgment. And this would be one way of reducing that hurdle. Um, and getting more EVLPs done in the United States.

Ulrich Trattner
41:02 - 41:30

Yeah, sure. And one sort of broader question relating to NRP. And we're seeing, I guess we're all seeing the same type of publications coming out and news that NRP is gradually gaining traction, mainly in heart and liver. But can you remind us how it fits into your product portfolio and correct me if I'm wrong? My understanding is that it's mainly used as a complementary method to your product portfolio.

Christoffer Rosenblad
41:30 - 43:34

Yeah. Yeah, that is correct. I mean, to start with, we really welcome NRP. It's an, it's an addition to the transplant world and it adds more organs from the DCD donor pool. It's also very complementary to our product portfolio. Um, if you look at it, it's obvious for, uh, heart, liver, and kidney where the kidney and heart are transported. So you would still need to transport them after NRP, and the liver is back to base where you, let's say, pump the organ before transplantation to reoxygenate the organ. So if you do NRP or not, it doesn't change the equation. So to say, if it's not a very short transport, for lungs and EVLP, the guidelines are that when you do Abdominal NRP, which is mainly for the liver and/or kidney, then there is no problem taking the lungs because there would be no damage done to the lungs. And you include the lung and the heart. You do it to evaluate and recover the heart. The risk is that you damage the lungs. So we see that LP is actually a tool to increase the number of lungs taken care of after NRP, where today you do it for the heart, and you very often have to discard the lung because of insecurity when you perfuse the lung under too high pressure. So the guideline is that you should be careful using lungs from NRP. But we believe that with EVLP, you can use those lungs as well. So that's why we view it as a great complement to both the transplant world and to our product portfolio.

Ulrich Trattner
43:36 - 44:00

Great. Um, if you look at it, it's obvious for, uh, heart, liver and and kidney where the kidney and heart are transported. A few more short questions. Um, our Australia Q1 sales show really strong momentum. I remember it must have been 1 or 2 years ago when we had a similar situation in Australia, and that was followed by a few weaker quarters where there was some inventory build-up. Is this the case now, or is there something different?

Christoffer Rosenblad
44:01 - 45:10

We see higher penetration this quarter compared to last year. Full year. Um, we could it could always be quarter by quarter. Uh, let's say stocking and destocking, because there are few clinics. And if they have, uh, one, two, or three kits on the shelf, it will affect our growth rate. So I think when we look at growth, we should rather focus on a 12-month rolling basis. It's just very encouraging to see that there is high interest; it is an increasing penetration. And, uh, we do see that we need better proof on DCD hearts, both with or without NRP. I mean, you can do NRP, which was included in our heart trial. You can do direct procurement, which we're now trialing in Europe on 40 patients in the Benelux. Um, and we will also trial in Australia soon. We are, uh, right now conducting pre-clinical trials on DCD hearts in Australia. So we do see to really get the usage up, we have to be able to use both EVD and DCD in Australia, Europe, and the United States.

Ulrich Trattner
45:12 - 45:23

Great. And last question, and it's a short one for Nordström. Net financials were -41 million in Q1. What's the explanation behind this?

Kristoffer Nordström
45:24 - 45:35

It's, uh, that's non-operational. So it's primarily the weakened US dollar and its effect on not only cash but also our other balance items.

Ulrich Trattner
45:36 - 45:39

Great. So, mainly, it's a sort of revaluation of receivables.

Kristoffer Nordström
45:39 - 46:01

Great. And since the biggest kind of. Well, we don't know, of course, but I think we had a big hit in Q1 because there was a significant devaluation of the US dollar. And if that stabilizes, I think that effect should be less on the financial item side in the next quarters. But who am I to judge?

Ulrich Trattner
46:04 - 46:08

Okay, great. Um, that was all questions on my end, and I'll get back into the queue. Great.

Christoffer Rosenblad
46:09 - 46:09

Thank you.

Operator
46:15 - 46:20

The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.

Philip Wiberg
46:23 - 46:45

Hi. Good afternoon. I've got a couple of questions here on the Dxps. Um, so are the deliveries for new expenses set for the end of the quarter? Um, so I was just wondering if you could give some more details around the type of customers. Are those high volume or low volume customers? What could you say about them?

Christoffer Rosenblad
46:46 - 47:19

Thank you, Philip. Very good question. Um, we are definitely excited. There are, um, high volume customers. Uh, they are the ones showing the greatest interest in starting an EVLP program. You need to do a certain number of lungs per year in order to sustain an EVP program. And one of them is a very reputable, top-ten customer in the United States. Uh, that was included this quarter. Um.

Philip Wiberg
47:23 - 47:35

Uh, they are the ones showing the greatest interest in starting an EVLP program. Uh, they are the ones that are showing the greatest interest in starting an EVLP program. Good to hear. And I guess they are up and running immediately. Is there any delay before they are? I guess they have to ramp up utilization. But is it, how long does it take?

Christoffer Rosenblad
47:36 - 48:36

Uh, yeah, that's a great question. This is something we're working on. Uh, it takes too long today, and we are working on shortening that time frame. Uh, so once you deliver an XPS, you then have a training, uh, followed by a couple of cases, trial runs, and then you go live. We have historically seen that from the time someone sends a PO until they are up and running, it. It could be 6 to 9 months, but we are working actively to reduce that time to 2 to 3 months. But today, unfortunately, it takes some time due to very practical reasons, such as needing a training lung and not knowing when there will be a discarded human lung available for training. Uh, but we are running a project to reduce this, let's say, startup time dramatically from where it is today to where it should be in the future.

Philip Wiberg
48:38 - 48:46

Okay, thanks. Very clear. It's a gradual ramp-up. It takes some time, but it's going to increase right away after they have done this trial on them.

Christoffer Rosenblad
48:47 - 49:00

Uh, they are the ones that are showing the greatest interest in starting an EVLP program. So typically, once they are fully trained and fully certified, they ramp up pretty quickly. But it takes too long to get them fully trained until ramp-up today.

Philip Wiberg
49:01 - 49:21

Yeah. Uh, they are the ones that are showing the greatest interest in starting an EVLP program. Thanks for that. And the other point on the agenda is about the production. So I was just wondering if there is any new problem here around the production constraint on the machine, or have you had the same production capacity for a long time? And it's just that the demand has increased now. How do you explain this?

Christoffer Rosenblad
49:21 - 50:06

Yeah, it's a combination. What happened was that last year we had, uh, a couple of obsolete products in the XPS that we needed to change. That change took longer than we expected to both get the right products in and get them approved. So we could sell the XPS again. Uh, that work is now finalized. Um, and we are slowly ramping up. The other thing that happened is that there is higher interest than we expected. So those two in combination are not great. Of course, when you have a six-month non-delivery period and then greater interest than we have ever seen before, it creates challenges. So it's a combination of the two.

Philip Wiberg
50:09 - 50:21

And the other one on the expressway is around production. And the other one on the expressway is around the production. But it also sounds like you're talking about how much you're going to produce for the remainder of the year, but you sound highly confident that you're going to be able to sell all of those. Is that correct?

Christoffer Rosenblad
50:21 - 50:21

And the other one on the XPS is around the production.

Philip Wiberg
50:21 - 50:22

That's correct.

Christoffer Rosenblad
50:22 - 50:23

Yes, that is correct.

Philip Wiberg
50:25 - 50:32

And the other one on the expressway is around the production. Well, that sounds encouraging. All right. Yeah. And the other one on the expressway is around the production. That's all for me. I'll get back into the queue. I'll get back into the queue. And the other one on the expressway is around the production.

Christoffer Rosenblad
50:33 - 50:33

Thank you.

Operator
50:39 - 50:44

The next question comes from Maria Vara from Bayon Garnier and Company. Please go ahead.

Maria Vara
50:46 - 51:19

Good afternoon. Thank you for taking my questions. I just wanted to first follow up on the previous questions about the time it takes to train professionals on using the machine, but more in relation to the heart technology. If I recall from your report, you said that all of the initial interest is well trained, but I was wondering how long it takes to actually get trained for heart technology. Is it similar to the lung technology and do you foresee any other educational programs ahead of the launch in Europe?

Christoffer Rosenblad
51:20 - 52:29

That's actually a great question. We have seen that the heart is a lot easier. So again and again. We've seen that a clinic can be up and running very fast. We're talking about 1 to 3 months for the heart technology, and they are more or less fully proficient in using the heart technology after running only three, let's say, real cases. So, there is a learning curve for heart, but it's very, very steep compared to the learning curve for lung, as evaluating a lung is a little bit more complicated than just perfusing a heart, so to say. So, we don't foresee the same problem, but we have to be very humble about the fact that there is a training period needed for the heart. And we know that there is a need to do three real cases before being fully up and running. So, we don't foresee a significant training phase here in Europe. But that is because we did. We ran the trial before.

Maria Vara
52:31 - 53:04

The next question comes from Maria Vara from Bayon Garnier and Company. That's very helpful. And then I wanted to get a bit more information on the DeLIVER Trial. Um, it's great news that you got the approval to start enrollment. Uh, I was wondering if you could share some details on the expected time for enrollment, considering you're going to enroll about 200 patients. If we could consider a similar rate of enrollment compared to the US trial to get a sense, a bit of, you know, when the enrollment will be finalized and then potential approval could be more towards 2028 or a bit earlier. The next question comes from Maria Vara from Bayon Garnier and Company.

Christoffer Rosenblad
53:06 - 53:44

The next question comes from Maria Vara from Bayon Garnier and Company. Yeah. If you have a similar enrollment rate as in the heart trial, it will take a comparable amount of time. Since it's more patients, it will take somewhere between 24 to 26 months. Um, and that is also what we're aiming. Uh, I would like to come back when we see, uh, let's say the few centers in to thoroughly test that if we see a faster enrollment or slower, we know the interest is very high. So we hope for a little bit faster. But if we do a 1 to 1 comparison, it's rather a 24-month, uh, let's say, timeline. We're looking into that more than anything else.

Maria Vara
53:46 - 53:58

Uh, I would like to come back when we see, uh, let's say the few centers that are currently conducting tests. If we see a faster enrollment or slower enrollment, we know the interest is very high. That's helpful. And in terms of sales that we could expect from the US trial and DeLIVER, is it going to be charged or at least do you aim to charge a similar price to the US trial?

Christoffer Rosenblad
54:00 - 54:17

It will be similar, but slightly lower was the last I heard. We're still in negotiations. We don't know the final price. Uh, it will be slightly lower if I understood correctly. Uh, I would like to come back when we see, uh, let's say the few centers in to torture test that if we see a faster enrollment or slower, we know the interest is very high. Um, from the last correspondence, which seems.

Maria Vara
54:19 - 54:43

All right. And then maybe a last question. Uh, it's great news that you got the continued access protocol for heart. However, I was wondering if this six-month allowance for up to 60 patients means that you will only be able to do it for the upcoming six months, and then this continued access protocol will stop. Or does it mean that it will re-initiate again, allowing you to continue with the protocol until you get approval?

Christoffer Rosenblad
54:44 - 55:03

The correspondence we got from the FDA was that it will be renewed based on safety data. So, they will have a quick review next time and look at the safety data to renew it until US approval. That's the last thing we heard from the FDA.

Maria Vara
55:05 - 55:07

Uh, I would like to come back when we see, uh, let's say the few centers in to torture test that if we see a faster enrollment or slower, we know the interest is very high. That's very helpful. Thank you very much.

Christoffer Rosenblad
55:08 - 55:09

Uh, I would like to come back when we see, uh, let's say the few centers in to torture test that if we see a faster enrollment or slower, we know the interest is very high.

Operator
55:14 - 55:18

The next question comes from Johan Honoris from Redeye. Please go ahead.

Johan Honoris
55:21 - 56:09

Hi. Well, thank you for taking our questions. Some of them have actually been answered already. And yes, to revisit the impact of tariffs, just for clarification. It seems to be a rather modest impact on your part. You operate with high margins, especially on the consumable side, and you operate through a US subsidiary. And presumably the tariff will be based on a price level closer to COGS. And historically, you have also been in a very good position to be able to review your prices. And your prices are still relatively modest compared to some of the competition. Is that a fair picture?

Christoffer Rosenblad
56:10 - 57:16

Yes, that is an accurate representation. So, we are lower compared to the competition. Uh, we have unique products, which are in many cases a fraction of the total cost of a transplant per organ. We believe that there will be an ability to recover the tariffs by price increases for those products. That being said, when we're running a trial and there is a CMS-set reimbursement or cost recovery, we can't change the prices because they are set by CMS. So for example, in the heart trial, we can't change prices, nor can we for the future cost recovery for the liver, as they will be fixed prices. So, uh, to be clear, there we can. But that's a limited number of patients and a limited, uh, let's say amount. And, we don't foresee that it will have a huge impact on our profitability.

Johan Honoris
57:19 - 57:56

Thank you. That's useful. And also, the expense has been explained. You had some review of earlier products together with higher demand than expected, and it will take some time for you to match the demand level, which is structurally positive, of course. And what about on the lung side of the supply? There have been some glitches on that side as well. What can we expect? Where will you be fully operational or? This is a minor issue.

Christoffer Rosenblad
57:56 - 58:39

Now we believe that in terms of expenses, we will hopefully be fully up and running and meet the customer demand in Q4. Uh, we are certainly working very hard towards that. Um, so we will do our utmost regarding the disposables, we don't foresee any shortages there. Uh, we have enough production capacity, uh, for the, uh, for the next two years. Uh, over time, we will increase production capacity of disposables for lungs. But for the next two years, we believe we can meet demand.

Johan Honoris
58:42 - 59:41

Thank you. That's also useful. And also, regarding the continuous, well, the compassionate use or continuous protocol. And you got the clearance. The first patients are expected during this quarter. Um, you will be able to sort of activate some of these patients during the first six-month period, and then they will undergo a safety review and then another six months. What should we do? This is, of course, very important and interesting in terms of gaining clinical experience and continuing to activate clinics and centers, but there is limited impact on sales. But what can we do, and how long will it take to activate all 16? And is this a set number even if you extend the additional six-month period?

Christoffer Rosenblad
59:43 - 60:47

Uh, yeah, that is a great question. I think in the beginning we will try to be very sharp and talk to the ones who believe that they can't live without the heart box. We have a few clinics in the US who have said that during the down period, they have patients dying on the waiting list because they don't have access to the heart box. We will target those first, because this is still viewed as a new clinical trial from each hospital's side. So we have to renew the IRB and we have to renew the contract. Uh, so of course they look exactly the same as the old one, but it still has to go through, uh, an IRB and, and, uh, clinical trial process in the hospital. So it is a bit of administrative work. So we will target a few clinics in the beginning and then reassess to see how many resources we have and whether we should target all of them or not. That decision has not been made yet.

Johan Honoris
60:50 - 61:37

But for the next two years, we believe we can meet demand. Thanks. That's also useful. And that touches on the services side. This is of course under review. And it's a sort of a mix where the current setup is more tailored towards heart, which will of course be in use also during this clinical protocol stage. It's too early to say anything specific about these services, but of course, it's a critical operation. It's important that you have the support for this. Um, it's also an issue of what sort of sales resources we should review since your services business is viewed more as a supporting business at this stage.

Christoffer Rosenblad
61:38 - 62:35

But for the next two years, we believe we can meet demand. Um, we heard from many heart transplant clinics that said you have a fantastic product, but you need to pair it with a good organ recovery service business to capture all heart transplants in the US. So there's a bit of work to be done there for sure. Um, so it is very strategically important for the heart. Uh, so what we hope to do is to gain the ability during the continuous access protocol for our Organ Recovery Service to train on the hot box together with clinics. So we are fully up and running when we launch the heart. So that is part of the strategic review we are doing now together with a third party, to make sure that we are ready when we have approval of the heart in the United States.

Johan Honoris
62:38 - 62:46

And what about benefiting from the services side on the lung business? Is that more of a challenge?

Christoffer Rosenblad
62:48 - 64:18

Uh, it is more of a challenge. The current organ recovery service we have is not 100% tailored towards the lung business. Uh, we need more of the Italian model, which we have shown great progress on liver, for example. Uh, and that model works very well, so we need to have a two-phased approach here. First, we have to make sure that we have an organ recovery service that will be second to none when we launch heart. And secondly, we need to establish a perfusionist and organ recovery service for lungs. So we have, um, we can build that organ recovery service until the heart launch, so to say. So we don't have to start that work, as lung is the only thorax product we have approved in the US, which would be perfect to have a great service around the two of them. So we do see that we need to add more perfusionists to our service offering to be relevant in lung, which we do acknowledge we are not relevant in right now. We have surgeons out there who recover hearts or lungs, and they very often recover hearts. And they see those are really good lungs. Uh, so if they had a place to send those lungs, it would be with a perfusionist. That would be great too. So we use more lungs from the donor pool.

Johan Honoris
64:20 - 64:30

Interesting. And presumably with the dynamics, that need may even increase.

Christoffer Rosenblad
64:31 - 65:07

Yes, we believe so. If we could have access to a perfusionist close to an NRP site, that would be beneficial. So we could send the lungs directly to, uh, to LP. This is what they do in France. They have a special protocol where they actually take the lung, and then they can perform NRP without damaging the lung, with very good success rates. So, um, that's something that would be very good. But then we also need to pair our service offering with an NRP service. So that would be part of our review as well.

Johan Honoris
65:08 - 65:14

Yeah. And this will take some time to both decide and implement. Of course.

Christoffer Rosenblad
65:15 - 65:22

True. I mean, once we implement, we will act swiftly. But we first have to make sure that we do our homework.

Johan Honoris
65:24 - 65:25

Excellent. Thank you.

Operator
65:35 - 65:39

The next question comes from Jacob Lemke from SEB. Please go ahead.

Jacob Lemke
65:43 - 66:13

Thank you. I know we're probably running over time, but it should be a quick question on liver. Uh, it's, you know, a bit of a better quarter than recently. And I know that. Or at least it seems like Italy, which is a key market for you in liver, in general, had somewhat slower growth for liver last year. And given what you see now, do you see Italy improving? Do you see Italy improving? And in general, the outlook for liver in Europe for 2025.

Christoffer Rosenblad
66:14 - 68:02

That's a great question. Liver is one of those organs where we have all the prerequisites to become gold standard over time, especially in Europe, because all the clinical data shows that it's good for the liver, it's good for the patient. It also saves money for the hospital because there is less aftercare. So, uh, and lastly they can actually start to plan surgery. What we have in Italy is the perfusionist model where we support them by pumping the organ as well. So we don't put a restraint on the hospitals by having liver. So we definitely see that we need to spread that model into the rest of Europe. Um, we actually see growth in more countries than just Italy. So we see Italy is definitely back to a higher growth rate compared to last year. Um, but we have to look at it more comprehensively on a 12-month rolling basis going forward. Uh, 12 months, uh, quarter by quarter. It could be jumpy, but we do foresee pretty good growth in the liver segment, um, due to the positive clinical results. But also, we are nearing that phase in liver where it becomes almost like a general practice to have a liver device. Now we are between 14% to 25% market penetration country by country in Europe. And that is typically where we are. We go from being an investigational device to a market practice. So we do see that we have all the prerequisites for growth. Now, I think it's up to that. We have a large enough sales force to actually capture that growth.

Jacob Lemke
68:05 - 68:16

Okay, that sounds very promising. And you shortly, did I interpret it correctly, that you have gotten confirmation that you can get reimbursed for the cases in the DeLIVER Trial.

Christoffer Rosenblad
68:16 - 68:29

And we do not have confirmations. We are in negotiations with CMS regarding cost recovery in the US trial, if that's what you refer to. We have not yet received confirmation.

Jacob Lemke
68:31 - 68:33

It could be jumpy, but we do foresee a pretty good growth in liver, um, due to the good clinical results. Uh, that's all for me. Thank you very much.

Christoffer Rosenblad
68:34 - 68:53

Thank you. I think we are almost 15 minutes over time. So with that, it concludes the meeting. And, uh, I hope to meet all of you on July 11th, uh, when we will report Q2 results. Thank you very much. And see you next time.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…